We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Mirum Pharmaceuticals Inc | NASDAQ:MIRM | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.03 | -0.12% | 24.46 | 23.50 | 25.92 | 24.785 | 24.17 | 24.43 | 268,335 | 22:30:00 |
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that company management will participate at the following conferences in February and March.
A live audio webcast and archive of the presentations outline above will be available at http://ir.mirumpharma.com
Additionally, the company will be participating the 32nd Annual ROTH Conference, and will be on a panel on Monday March 16 at 11:00 a.m. discussing Orphan Therapeutics.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). For more information, visit MirumPharma.com. Follow Mirum on Twitter, Facebook and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200218005870/en/
Media Contact: Heidi Chokeir, Ph.D. Canale Communications 619-203-5391 heidi@canalecomm.com
Investor Contact: Ian Clements, Ph.D. 650-667-4085 ir@mirumpharma.com
1 Year Mirum Pharmaceuticals Chart |
1 Month Mirum Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions